791049-17-7

Upstream product

• 40928-13-0 4-chloroisatoic anhydride 
• 252232-88-5 1-[[3-(7-chloro-3,4-dihydro-6-nitro-4-oxo-2-quinazolinyl)propoxyphenyl]sulfonyl]-4-methylpiperazine 
• 252232-83-0 4-chloro-2-[(2-propoxybenzoyl)amino]-5-nitrobenzamide 
• 252232-81-8 7-chloro-1,4-dihydro-6-nitro-2H-3,1-benzoxazine-2,4-dione 
• 252233-03-7 1-[[3-(7-amino-3,4-dihydro-6-nitro-4-oxo-2-quinazolinyl)propoxyphenyl]sulfonyl]-4-methylpiperazine 
• 252232-85-2 4-chloro-6-nitro-2-(2-propoxyphenyl)-4(3H)-quinazolinone 
• 252232-80-7 2-amino-4-chloro-5-nitrobenzamide 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 54090-36-7 2-propoxybenzoyl chloride 

Relevant academic research and scientific papers

Quinazolinone inhibitors of cGMP phosphodiesterase

Novel quinazolinone compounds, methods of using such compounds in the treatment of cGMP-associated conditions such as erectile dysfunction, and pharmaceutical compositions containing such compounds.

N-3-substituted imidazoquinazolinones: Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction

Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describe